CERVARIX - 58160-830-32 - (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant)

Alphabetical Index


Drug Information of CERVARIX

Product NDC: 58160-830
Proprietary Name: CERVARIX
Non Proprietary Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Active Ingredient(s): 20; 20    ug/.5mL; ug/.5mL & nbsp;   Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Administration Route(s): INTRAMUSCULAR
Dosage Form(s): INJECTION, SUSPENSION
Coding System: National Drug Codes(NDC)

Labeler Information of CERVARIX

Product NDC: 58160-830
Labeler Name: GlaxoSmithKline Biologicals SA
Product Type: VACCINE
FDA Application Number: BLA125259
Marketing Category: BLA
Start Marketing Date: 20091016

Package Information of CERVARIX

Package NDC: 58160-830-32
Package Description: 1 SYRINGE in 1 CARTON (58160-830-32) > .5 mL in 1 SYRINGE

NDC Information of CERVARIX

NDC Code 58160-830-32
Proprietary Name CERVARIX
Package Description 1 SYRINGE in 1 CARTON (58160-830-32) > .5 mL in 1 SYRINGE
Product NDC 58160-830
Product Type Name VACCINE
Non Proprietary Name Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Dosage Form Name INJECTION, SUSPENSION
Route Name INTRAMUSCULAR
Start Marketing Date 20091016
Marketing Category Name BLA
Labeler Name GlaxoSmithKline Biologicals SA
Substance Name HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN RESIDUES 2-471 ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN RESIDUES 2-472 ANTIGEN
Strength Number 20; 20
Strength Unit ug/.5mL; ug/.5mL
Pharmaceutical Classes

Complete Information of CERVARIX


General Information